Pear Therapeutics Expands Pipeline with Machine Learning, Digital Therapeutic and Digital Biomarker Technologies - Pear Therapeutics

Boston and San Francisco, January 7, 2020 – Pear Therapeutics, Inc., the leader in Prescription Digital Therapeutics (PDTs), announced today that it has entered into agreements with multiple technology innovators, including Firsthand Technology, Inc., leading researchers from the Karolinska Institute in Sweden, Cincinnati Children's Hospital Medical Center, Winterlight Labs, Inc., and NeuroLex Laboratories, Inc. These new agreements continue to bolster Pear's PDT platform, by adding to its library of digital biomarkers, machine learning algorithms, and digital therapeutics. Pear's investment in these cutting-edge technologies further supports its strategy to create the broadest and deepest toolset for the development of PDTs that redefine standard of care in a range of therapeutic areas. With access to these new technologies, Pear is positioned to develop PDTs in new disease areas, while leveraging machine learning to personalize and improve its existing PDTs. "We are excited to announce these agreements, which expand the leading PDT platform," said Corey McCann, M.D., Ph.D., President and CEO of Pear.